Cure My Disease

Don't miss your cure!

 Log in / Sign up

One pill, three medicines: a new hope for stubborn high blood pressure?

NCT ID NCT07784296

Disease control Sponsor: Hanmi Pharmaceutical Company Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This study looks at how well a single tablet combining three blood pressure medicines—amlodipine, losartan, and chlorthalidone—works in Korean adults with hypertension. Researchers will track changes in blood pressure over six months and note any side effects. The goal is to see if this triple therapy helps patients who are newly diagnosed or not well controlled on one drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A fixed-dose combination tablet containing amlodipine, losartan, and chlorthalidone (Amoprel)
What this could lead to
If effective, this triple-drug combination could offer a convenient once-daily option to help more Korean patients with hypertension reach their blood pressure goals.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient differences. Side effects like dizziness or electrolyte imbalances are possible with the included diuretic.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

General hospital

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Korean patients aged 19 years or older diagnosed with hypertension 2. Individuals newly diagnosed with hypertension or currently taking a single antihypertensive drug 3. Individuals for whom administration of Amoprel tablets has been determined based on the researcher's medical judgment 4. Individuals who have heard an explanation of this study and have voluntarily given written consent to participate in the study Exclusion Criteria: 1. Individuals falling under the contraindications listed in the precautions for use of Amoprel Tab. or Amozartan Plus Tab. 2. Pregnant women, women who may be pregnant, and nursing mothers 3. Individuals currently participating in an interventional study 4. Individuals deemed unsuitable for participation in this study by the researcher for other reasons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Yongin Severance Hospital

    RECRUITING

    Gyeonggi-do, 16995, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.